Maze Therapeutics, Inc. SEC Filings

Maze Therapeutics, Inc. director Neil Kumar has filed an initial Form 3, identifying himself as a reporting person for the company’s stock. The filing lists no reportable transactions or holdings, with all transaction counts and share amounts in the transaction summary shown as zero.

MAZE: Notice of proposed sale of 30,000 common shares via option exercise. The filing lists 30,000 shares to be sold on 03/30/2026 through the exercise of stock options for cash. The record shows two prior 10b5-1 sales by Atul Dandekar: 7,500 shares on 02/27/2026 for $340,722.75 and 7,500 shares on 01/29/2026 for $331,990.50. The filing references 49,708,658 shares outstanding as of 03/30/2026.

Maze Therapeutics files its annual report outlining rapid progress in kidney and metabolic disease programs built on its human genetics–driven Compass platform. The company is a clinical-stage biopharma with no product revenue, focused on small‑molecule precision medicines.

Lead candidate MZE829, an APOL1 inhibitor for APOL1‑mediated kidney disease, showed positive Phase 2 proof‑of‑concept data, with a 35.6% mean reduction in urinary albumin‑to‑creatinine ratio at week 12 in evaluable patients and larger reductions in key subgroups. Maze plans to continue Phase 2 enrollment and move into pivotal development.

MZE782, targeting SLC6A19, completed a Phase 1 trial in healthy volunteers, was well tolerated, and produced large, dose‑dependent increases in urinary phenylalanine excretion, supporting Phase 2 trials in phenylketonuria and chronic kidney disease planned for 2026. The report also highlights partnered programs, including MZE001 for Pompe disease, licensed to Shionogi with a $150 million upfront payment, and neurology and ophthalmology collaborations that validate the Compass platform and diversify potential future revenue.

Maze Therapeutics reported a pivotal year, combining strong clinical progress with a fortified balance sheet. The company announced positive Phase 2 HORIZON data for MZE829 in APOL1-mediated kidney disease, showing a 35.6% mean proteinuria reduction at week 12 and no serious treatment-related safety issues, and plans to advance the drug into a pivotal program.

Maze is also preparing two Phase 2 proof-of-concept trials for MZE782 in phenylketonuria and chronic kidney disease in 2026, and recorded a $20 million milestone from partner Shionogi tied to the Phase 2 ESPRIT trial of Pompe candidate MZE001. Cash, cash equivalents and marketable securities reached $360.0 million as of December 31, 2025, providing expected runway into 2028.

For 2025, Maze reported a net loss of $131.1 million as it increased R&D spending to $108.4 million and G&A to $34.5 million, compared with prior-year license revenue of $167.5 million that had produced net income. The company also strengthened governance by appointing BridgeBio founder and CEO Neil Kumar to its Board of Directors, with an equity grant vesting over three years.

Maze Therapeutics, Inc. President, R&D & CMO Harold Bernstein exercised stock options to acquire 15,000 shares of common stock at $10.42 per share. On the same day, he sold those 15,000 shares in open-market transactions at weighted average prices between $47.77 and $50.52 per share. The sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025, indicating a scheduled liquidity event rather than a discretionary trade.

Maze Therapeutics, Inc. President, R&D & CMO Harold Bernstein exercised stock options for 30,000 shares of common stock at an exercise price of $10.42 per share and then sold 30,000 shares in open-market transactions on the same date.

The sales were executed in two tranches at weighted-average prices of $50.4454 and $51.0150 per share under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025. Following these transactions, he reported direct ownership of 0 common shares and 267,407 options remaining from the underlying award, which continues to vest monthly through October 2027.

MAZE files a Form 144 to sell 74,853 shares of Common Stock via exercise of stock options on 03/10/2026. The filing lists prior 10b5-1 dispositions by Harold Bernstein, including sales of 45,000 shares on 12/29/2025 and 25,156 shares on 01/07/2026

The notice states the method as cash proceeds from the option exercise; timing and final cash‑flow details follow the exercise on 03/10/2026.

Tahir Misbah reported acquisition or exercise transactions in this Form 4 filing.

Maze Therapeutics, Inc. reported that Chief Financial Officer Tahir Misbah received equity awards consisting of a stock option for 40,000 shares and 20,000 restricted stock units, both granted at a price of $0.00 per share.

The option award vests monthly in 1/48 increments, with the first portion vesting on April 1, 2026, as long as he continues serving the company. The restricted stock units vest in four equal annual installments, starting on March 1, 2027, with each unit representing the right to receive one share of common stock when it settles. These RSUs either vest or are cancelled before vesting.

Courtney Phillips reported acquisition or exercise transactions in this Form 4 filing.

Maze Therapeutics, Inc. reported that its General Counsel and Corporate Secretary, Courtney Phillips, received equity awards consisting of stock options and restricted stock units. The grant covers 32,000 options that vest monthly over four years starting on April 1, 2026, and 16,000 RSUs that vest annually in four equal installments beginning on March 1, 2027, in each case conditioned on continued service.